These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15257231)

  • 21. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
    Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
    N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined thiazolidinedione-insulin therapy: should we be concerned about safety?
    Scheen AJ
    Drug Saf; 2004; 27(12):841-56. PubMed ID: 15366973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pioglitazone. Review of its metabolic and systemic effects].
    Rodríguez Bernardino A; Cebrián Blanco S; Durán García S
    Rev Clin Esp; 2005 Dec; 205(12):610-20. PubMed ID: 16527183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Medication of the month. Rosiglitazone (Avandia)].
    Scheen AJ
    Rev Med Liege; 2002 Apr; 57(4):236-9. PubMed ID: 12073798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of thiazolidinediones beyond glycaemic control.
    Kalaitzidis RG; Sarafidis PA; Bakris GL
    Curr Pharm Des; 2009; 15(5):529-36. PubMed ID: 19199979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome].
    Bahia L; Aguiar LG; Villela N; Bottino D; Godoy-Matos AF; Bouskela E
    Arq Bras Cardiol; 2006 May; 86(5):366-73. PubMed ID: 16751941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonhypoglycemic effects of thiazolidinediones.
    Parulkar AA; Pendergrass ML; Granda-Ayala R; Lee TR; Fonseca VA
    Ann Intern Med; 2001 Jan; 134(1):61-71. PubMed ID: 11187421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral antihyperglycemic treatment options for type 2 diabetes mellitus.
    Brietzke SA
    Med Clin North Am; 2015 Jan; 99(1):87-106. PubMed ID: 25456645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current role of thiazolidinediones in diabetes management.
    Rizos CV; Kei A; Elisaf MS
    Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study].
    Slama G; Eschwège E; Bernard MH; Grimaldi A; Oppert JM; Pouchain D; Bégaud B;
    Ann Endocrinol (Paris); 2008 Feb; 69(1):36-46. PubMed ID: 18243155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS
    Am J Health Syst Pharm; 2007 Dec; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.